Follow The Filings

PLRX Pliant Therapeutics Inc.

Health Care, filed as PLIANT THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.1%
  • $555K

Who owns this now

Largest portfolio weights among holders, up to 0.1% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel 0.11%

Who owns PLRX

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.11% Hold 487,000 $555K History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by PLRX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PLRX insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 4 sales to cover taxes.

Congress

No member of Congress reported trading PLRX in the last three years. 1 member listed it in 2025 annual reports.

All Congress trades

SEC filings

Recent issuer filings from EDGAR, 19 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02 Filing Doc
8-K 8.01 Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 1.01,3.03,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.58M $0M $0M
Net income -$161.34M -$210.3M -$149.34M
Net margin * -10211.1% — —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $505.5M $362.26M $196.45M
Total non-current assets * $6.65M $34.68M $28.78M
Total assets $512.15M $396.95M $225.23M
Total current liabilities $28.52M $33.22M $16.36M
Total non-current liabilities * $10.05M $59.65M $27.66M
Total equity $473.58M $304.08M $181.2M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$116.36M -$155.5M -$128.34M
Cash from investing -$127.01M $140.34M $134.29M
Cash from financing $274.4M $23.12M -$31.7M
Net change in cash $31.03M $7.95M -$25.74M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.